# Recombinant Human LILRB2/ILT-4/CD85d Domain1&2 Protein

Catalog No.: RP00340 Recombinant

Swiss Prot

O8N423-1

### **Sequence Information**

SpeciesGene IDHuman10288

# Tags

C-His

## Synonyms

CD85d; ILT4; ILT-4; ILT4CD85d; LILRB2; LIR2; MIR10

# Product Information

Source	Purification
HEK293 cells	> 95% by SDS-
	PAGE∏> 95% by
	HPLC

Calculated MWObserved MW24.2 kDa25-30 kDa

#### Endotoxin

< 1 EU/ $\mu$ g of the protein by LAL method

#### Formulation

Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

#### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

# Contact

6	400-99	9-6126
$\times$	cn.market@abclonal.c	<u>com.cn</u>
€	www.abclonal.c	<u>com.cn</u>

#### Background

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles.

## **Basic Information**

#### Description

Recombinant Human LILRB2/ILT-4/CD85d Domain1&2 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln22-Val229) of Human LILRB2/CD85d/ILT4 Domain1&2 (Accession #Q8N423-1) fused with a C-His tag at the C-terminus.


#### **Bio-Activity**

#### Storage


Store at -20°C.Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.

Avoid repeated freeze/thaw cycles.







Human LILRB2 Domain 1&2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.




The purity of Human LILRB2 Domain 1&2 is greater than 95% as determined by SEC-HPLC.



Immobilized Human LILRB2 Domain1&2, His Tag at 0.5  $\mu$ g/mL (100  $\mu$ L/well) on the plate. Dose response curve for Anti-LILRB2 Antibody, hFc Tag with the EC<sub>so</sub> of 16.6ng/mL determined by ELISA (QC Test).



Human HLA-G Complex Tetramer, His Tag immobilized on CM5 Chip can bind Human LILRB2 Domain1&2, His Tag with an affinity constant of  $6.5\mu$ M as determined in a SPR assay (Biacore T200).



Serial dilutions of Anti-LILRB2 Antibody were added into Human LILRB2 Domain1&2, His Tag : Biotinylated Human HLA-G Complex Tetramer, His Tag binding reactioins. The half maximal inhibitiory concentration (IC<sub>50</sub>) is 0.43  $\mu$ g/mL.